Metastatic CRPC Patient Identification

Metastatic CRPC Is Common

Most men with castrate-resistant prostate cancer (CRPC) will eventually develop metastatic disease.1-3

Learn more about diagnosing mCRPC

PROVENGE Treatment Window

In the newly metastatic CRPC patient who is asymptomatic or minimally symptomatic, there’s a PROVENGE window.

Learn more about the PROVENGE treatment window

For the Newly Metastatic CRPC Patient

61% of men are PROVENGE-eligible at diagnosis of metastatic CRPC.4

Identify PROVENGE patients

Discuss PROVENGE With Your Patients

Help your patients understand treatment with PROVENGE.

Talk with your patients

  1. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Current Oncology. 2010;17(S2):S72-S79.
  2. National Comprehensive Cancer Network. Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. Version 1.2013. 1/20/13.
  3. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180-1192.
  4. Data on file. Dendreon Corporation.